Organon

🇺🇸 NYSE:OGN

Feb 13

•

Dec 31, 2024

Organon Q4 2024 Earnings Report

Key Takeaways

Organon's Q4 2024 revenue remained stable at $1.592 billion, with growth in Established Brands offsetting declines in Biosimilars. Net income fell significantly due to a one-time tax benefit in Q4 2023.

Total Revenue

$1.59B

Previous year: $1.6B

-0.4%

EPS

$0.9

Previous year: $0.88

+2.3%

Gross Margin

56.3%

Previous year: 57.3%

-1.7%

Adj. Gross Margin

60.6%

Previous year: 60.3%

+0.5%

Adj. EBITDA Margin

28.1%

Previous year: 28.1%

+0.0%

Gross Profit

$896M

Previous year: $915M

-2.1%

Cash and Equivalents

$675M

Previous year: $693M

-2.6%

Organon Revenue

Organon EPS

Organon Revenue by Segment

Organon Revenue by Geographic Location

Forward Guidance

Organon expects 2025 revenue between $6.125B and $6.325B, facing FX headwinds and Atozet’s loss of exclusivity. The company targets cost discipline to maintain an adjusted EBITDA margin of at least 31.0%.

Positive Outlook

2025 revenue expected to remain above $6.1B despite headwinds
Adjusted EBITDA margin projected to improve to 31.0%-32.0%
Continued expansion of Nexplanon and Hadlima sales
Disciplined cost management to protect profitability
Ongoing growth potential in women's health and biosimilars

Challenges Ahead

Approx. $200M FX impact expected in 2025 revenue
Loss of exclusivity for Atozet in key markets
Competitive pricing pressure in biosimilars segment
Higher inflation affecting material and distribution costs
Slightly lower adjusted gross margin guidance (60.0%-61.0%)

Revenue & Expenses

Visualization of income flow from segment revenue to net income